Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Maserati

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 2, 2011
Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infectionC Zucchella, E Sinforiani, E Tavazzi, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1996
Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 casesM Arlotti, G Zoboli, G L Moscatelli, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 18, 2001
Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapyM Debiaggi, F Zara, A Spinillo, et al.
HIV Clinical Trials|October 24, 2001
Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 studyG Carosi, F Castelli, F Suter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2001
Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAARTG Gerna, G Piccinini, E Genini, et al.
AIDS Research and Human Retroviruses|November 14, 1997
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistanceF Lori, A G Malykh, A Foli, et al.
The Journal of Antimicrobial Chemotherapy|July 18, 2009
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictorsL Bracciale, M Colafigli, M Zazzi, et al.
Neurology|February 26, 2000
Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & TumoriA Antinori, A Ammassari, R Luzzati, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2013
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA databaseS Rusconi, P Vitiello, F Adorni, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 2, 2011
Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infectionC Zucchella, E Sinforiani, E Tavazzi, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1996
Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 casesM Arlotti, G Zoboli, G L Moscatelli, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 18, 2001
Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapyM Debiaggi, F Zara, A Spinillo, et al.
HIV Clinical Trials|October 24, 2001
Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 studyG Carosi, F Castelli, F Suter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2001
Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAARTG Gerna, G Piccinini, E Genini, et al.
AIDS Research and Human Retroviruses|November 14, 1997
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistanceF Lori, A G Malykh, A Foli, et al.
The Journal of Antimicrobial Chemotherapy|July 18, 2009
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictorsL Bracciale, M Colafigli, M Zazzi, et al.
Neurology|February 26, 2000
Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & TumoriA Antinori, A Ammassari, R Luzzati, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2013
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA databaseS Rusconi, P Vitiello, F Adorni, et al.
Pageof 9